Rocket Pharmaceuticals(US:RCKT) GlobeNewswire News Room·2025-06-23 20:00Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price following the announcement of a clinical hold by the FDA [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths during the clinical trial [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. Stock Price Impact - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share, marking a decline of approximately 37% in just one trading day [3]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for August 11, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. Law Firm Background - The Gross Law Firm, which is leading the class action, is recognized for protecting investors' rights against deceit and fraud, aiming to recover losses incurred due to misleading statements by companies [5].